Episode 3/
Using artificial intelligence to counter COVID

10 March, 2021

A fairly new technology for medical settings, artificial intelligence (AI) has been critical for enabling deep insights and fast responses to the pandemic. In this podcast, we speak with scientists from three different companies on how they use AI to counter the pandemic, the challenges facing AI in a biomedical setting, and the real advantages that this powerful technology can bring to improve healthcare outcomes. Covering SARS-CoV-2 molecular diagnostic testing, patient management in the hospital, and SARS-CoV-2 diagnostic imaging, our guests bring together an impressive depth of knowledge and range of viewpoints on the implementation of AI in medicine.

Podcast Episode Image

Our Guests

Dries Hens, MD
Dries Hens is a co-founder of LynxCare, which aims to harness healthcare data with the sole goal of improving patient outcomes. He currently serves as the company’s Chief Business and Medical Officer. Dries completed his medical degree at KU Leuven Faculty of Medicine and completed a Masters of Science in Pharmaceutical Marketing and Management at the ESCP Business School.

James Grayson
James Grayson is a scientist and automation engineer with more than 10 years experience in laboratory workflow automation. James joined UgenTec in August 2019 as the Technical and Applications lead for the Americas and Australia helping to support customers and grow the UgenTec team and business in new markets. Prior to joining UgenTec, James was the Head of Molecular Workflow Automation at Siemens Healthineers, working to capture Voice of Customer Workflow needs and develop customized solutions.

Dirk Smeets, PhD
Dirk Smeets is the Chief Technology Officer at icometrix, a company founded to leverage artificial intelligence to transform patient care with data-driven insights. As a member of icometrix senior management, he serves multiple roles, including managing the research and development team. Dirk holds a PHd in medical image computing from KU Leuven.
Meet our host
Pia Abola, PhD
Pia Abola, PhD, has spent the past ten years providing content marketing for life science companies. Before becoming a marketer she used protein biochemistry and molecular biology to study site-specific recombination, plant-bacteria symbiosis, and signal transduction. She also worked on the human genome sequencing project and and at an anti-viral drug discovery company.
Next episode
The role of wastewater surveillance in the next phase of the COVID-19 pandemic

15 May, 2021

With many public health experts believing that COVID-19 will continue to be a global health problem for years to come, the need for SARS-CoV-2 testing will remain. However, the type of testing will likely change. For regions where the virus is not very widespread and the number of diagnostic tests has declined, surveillance testing of wastewater for SARS-CoV-2 can be an efficient and cost-effective way to understand and anticipate potential outbreaks.
In this episode, we speak with three scientists from Combinati, a company that has commercialised a digital PCR platform, on how their technology is being used by universities and municipalities in the United States to analyse wastewater for SARS-CoV-2 surveillance, and the unique advantages of digital PCR for this application.

Podcast Image

Enabling your rapid response to the pandemic

COVID Resource Hub